ReviewMedComm2026
RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA modifications are pivotal posttranscriptional gene expression regulators with profound functions in both physiological and pathological states, particularly during cancer initiation and progression. Within the complex tumor microenvironment (TME), these modifications orchestrate diverse mechanisms that significantly impact tumor growth, facilitate immune evasion, and drive therapeutic resistance. Recent advances have demonstrated their critical roles in shaping RNA metabolism and maintaining genome integrity, as well as modulating key stromal pathways such as immune responses, extracellular matrix remodeling, and vascular supply. Emerging evidence further suggests that RNA modifications dynamically regulate intercellular communication between tumor cells and surrounding stromal and immune cells within the TME. In this review, we provide a comprehensive overview of the mechanisms and functional roles of major RNA modifications, including adenosine, guanosine, and pseudouridine modifications. We discuss their regulatory roles in RNA metabolism and genome integrity, and examine their diverse functions within the TME, including immune regulation, tumor proliferation, extracellular matrix remodeling, and DNA damage response (DDR) pathways. Additionally, we highlight recent advances in therapeutic strategies targeting RNA-modifying enzyme and discuss their potential for improving cancer treatment. Collectively, targeting RNA modification represents a promising strategy for overcoming cancer resistance and improving clinical treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.